UROKINASE PLASMINOGEN-ACTIVATOR AND UROKINASE PLASMINOGEN-ACTIVATOR RECEPTOR IN BREAST-CANCER
UROKINASE PLASMINOGEN-ACTIVATOR AND UROKINASE PLASMINOGEN-ACTIVATOR RECEPTOR IN BREAST-CANCER
复制标题
DOI：
10.1002/ijc.2910610502
复制
发表时间：
1995-05-29
影响因子：
6.4
通讯作者：
DUFFY, MJ
中科院分区：
文献类型：
--
作者：
DUGGAN, C;MAGUIRE, T;DUFFY, MJ
尿激酶型纤溶酶原激活物(UPA)是一种丝氨酸蛋白酶，参与肿瘤的侵袭和转移。UPA在与膜结合受体(UPAR)结合时介导其作用。在这项研究中，我们发现在人类乳腺癌中，uPAR水平与uPA水平相关。然而，uPAR水平与纤溶酶原激活物系统的其他成分如组织型纤溶酶原激活剂(t-PA)、PAI-1或PAI-2无关。此外，uPAR水平与肿瘤大小、腋窝淋巴结状态或雌激素受体状态无关。在最佳切点的基础上，uPAR水平高的乳腺癌患者比受体水平低的患者预后更差。然而，作为乳腺癌的预后标记物，uPAR不如uPA那么强，我们的结果与模型系统的数据一致，表明uPA和uPAR都是转移所必需的。(C)1995年Wiley-Liss公司
Urokinase plasminogen activator (uPA) is a serine protease involved in cancer invasion and metastasis. uPA mediates its action while attached to a membrane-bound receptor (uPAR). In this investigation we show that uPAR levels correlate with uPA levels in human breast cancers. uPAR levels, however, do not correlate with other components of the plasminogen activator system such as tissue-type plasminogen activator (t-PA), PAI-1 or PAI-2. In addition, uPAR revels showed no correlation with tumor size, axillary-node status or estrogen-receptor status. On the basis of an optimum cut-oft point, patients with breast cancers containing high levels of uPAR had a worse prognosis than patients with low levels of the receptor. However, as a prognostic marker in breast cancer, uPAR was not as strong as uPA, Our results are consistent with data from model systems suggesting that both uPA and uPAR are necessary for metastasis. (C) 1995 Wiley-Liss, Inc.